FDA Approves Subcutaneous Formulation of Leqembi Iqlik

The U.S. Food and Drug Administration has approved a subcutaneous formulation of the Alzheimer's treatment Leqembi, branded as Leqembi Iqlik, which allows for at-home administration via a weekly autoinjector. This regulatory milestone is accompanied by significant deal-making in the oncology space, as AstraZeneca secured global rights to Dizal Pharmaceutical's lung cancer therapy Zegfrovy in a transaction valued at up to $1.5 billion. These developments underscore a dual industry focus on improving patient access through convenient delivery systems and strengthening pipelines in targeted oncology.

The FDA's approval of Leqembi Iqlik provides patients with early Alzheimer's disease the option to self-administer anti-amyloid therapy, moving away from traditional intravenous infusions. The subcutaneous regimen involves a weekly autoinjector delivering 500 milligrams through two 15-second injections, with a reduced maintenance dose option following 18 months of treatment. Clinical data from sub-studies of the Phase III Clarity AD trial supported the approval, demonstrating that the subcutaneous delivery provides exposure equivalent to the intravenous version. The product is slated for U.S. availability by late August.

In the oncology sector, AstraZeneca has expanded its portfolio by entering an exclusive license agreement with Dizal Pharmaceutical for the oral EGFR inhibitor Zegfrovy. The deal includes a $600 million upfront payment and up to $900 million in potential milestones, totaling $1.5 billion plus tiered royalties. Zegfrovy is currently the only oral targeted therapy approved in both the U.S. and China for non-small cell lung cancer tumors featuring EGFR exon 20 insertion mutations. The acquisition, expected to close in the second half of 2026, follows positive Phase III data suggesting the drug's potential as a first-line treatment.

Beyond specific drug approvals and acquisitions, industry experts are highlighting a significant education gap regarding the surge in GLP-1 medications. Kristen Hartzell, vice president of clinical services at RedSail Technologies, noted that while patient awareness of these therapies is high, understanding of proper dosing, side effects, and necessary lifestyle changes remains insufficient. This gap places pharmacists at the center of patient care, requiring manufacturers and providers to maintain consistent messaging across digital and in-person channels to ensure treatment adherence and effective management of gastrointestinal side effects.